Patent ID: 7629370

Claim:
A method of treatment of diseases and conditions selected from metabolic syndrome, insulin resistance, type 2 diabetes and complications thereof consisting essentially of peripheral neuropathy, renal insufficiency, retinopathy and obesity, in a mammal subject, said method comprising administering to the mammal in need of such treatment a compound of formula (I) or a pharmaceutically acceptable salt thereof in a therapeutically effective amount wherein in formula (I): W represents COOH group or —COO—C 1 -C 4 -alkyl group; Y represents NH or N—C 1 -C 10 -alkyl; Z represents S; X represents O, S, NH, N—C 1 -C 10 -alkyl, N-aryl, NSO 2 —C 1 -C 10 -alkyl, N—SO 2 -aryl, or N SO 2 -heteroaryl; R 1 to R 6 each independently represents hydrogen atom or a substituent selected from the group consisting of: C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, C 3 -C 7 -cycloalkyl, C 3 -C 7 -cycloalkoxy, C 1 -C 4 -thioalkoxy, C 3 -C 7 -cyclothioalkoxy, halogen atom, halogen-substituted C 1 -C 4 -alkyl, halogen substituted C 3 -C 7 -cycloalkyl, —NO 2 , —CN, —SO 2 —NH 2 , —SO 2 —NH—C 1 -C 4 -alkyl, —SO 2 —N(C 1 -C 4 -alkyl) 2 , —CO—C 1 -C 4 -alkyl, —O—CO—C 1 -C 4 -alkyl, —CO—O—C 1 -C 4 -alkyl, —CO-aryl, —CO—NH 2 , —CO—NH—C 1 -C 4 -alkyl, —CO—N(C 1 -C 4 -alkyl) 2 , aryl, and heteroaryl, said aryl and heteroaryl being optionally substituted with one or more substituents independently selected from the group consisting of C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, C 3 -C 7 -cycloalkyl, C 3 -C 7 -cycloalkoxy, C 1 -C 4 -thioalkoxy, C 3 -C 7 -cyclothioalkoxy, halogen atom; halogen substituted C 1 -C 4 -alkyl, halogen substituted C 3 -C 7 -cycloalkyl, —NO 2 , —CN, —SO 2 —NH 2 , —SO 2 —NH-C 1 -C 4 -alkyl, —SO 2 —N(C 1 -C 4 -alkyl) 2 , —CO—C 1 -C 4 -alkyl, —O—CO—C 1 -C 4 -alkyl, —CO—O—C 1 -C 4 -alkyl, —CO-aryl, —CO—NH 2 , —CO—NH—C 1 -C 4 -alkyl, and —CO—N(C 1 -C 4 -alkyl) 2 ; A represents C 1 -C 4 -alkyl, C 3 -C 7 -cycloalkyl, halogen-substituted C 1 -C 4 -alkyl, halogen-substituted C 3 -C 7 -cycloalkyl, aryl, heteroaryl, heterocyclyl, —NH—CO—C 1 -C 4 -alkyl, —N(C 1 -C 4 -alkyl)-CO—C 1 -C 4 -alkyl, —NH—CO-aryl, —N(C 1 -C 4 -alkyl)-CO-aryl, —N(C 1 -C 4 -alkyl)-CO—C 3 -C 7 -cycloalkyl, —NH CO—NH 2 , —NH—CO—NH—C 1 -C 4 -alkyl, —NH—CS—NH—C 1 -C 4 -alkyl, —NH—CO—NH-aryl, —NH—CS—NH-aryl, —SO 2 —C 1 -C 4 -alkyl, —SO 2 -aryl, or —SO 2 -heteroaryl wherein aryl and heteroaryl are optionally substituted with one or more substituents independently selected from the group consisting of C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, phenyl, CN, NO 2 and halogen atom, and heterocyclyl is optionally substituted with one or more substituents independently selected from the group consisting of C 1 -C 4 -alkyl, C 1 -C 4 -alkoxy, and halogen atom; and n represents an integer from 0 to 4, inclusive.